Redeye: Saniona - What to expect in 2018

In this update, we examine Saniona’s opportunities and challenges for the next 12 months. We believe 2018 and beginning 2019 will be a period of value drivers as ever seen before. Read more in the Research Update by Anders Hedlund:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Om oss

Saniona är ett forsknings- och utvecklingsbolag som bedriver läkemedelsutveckling av preparat som ska användas till sjukdomar i centrala nervsystemet, autoimmuna sjukdomar och behandling av smärta.